Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current oral treatments for erectile dysfunction.

J S Kalsi1, S Cellek, A Muneer

  • 1The Institute of Urology and Nephrology, University College London, 48 Riding House Street, London, W1P 7NN, UK. j.kalsi@ucl.ac.uk

Expert Opinion on Pharmacotherapy
|November 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Litigation in urology within NHS England: a contemporary analysis of costs and causes.

Annals of the Royal College of Surgeons of England·2026
Same author

Management of penoscrotal hidradenitis: a narrative review.

International journal of impotence research·2025
Same author

Systematic review of bilateral epididymal leiomyomas.

Annals of the Royal College of Surgeons of England·2025
Same author

Urinary incontinence and female genital lichen sclerosus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

OsHV-1 Promoter-driven Transgene Expression in Bivalve Cells: An In Vitro Study with an EGFP-tagged Oncogenic H-RasV12.

Environmental management·2025
Same author

Preventing penile cancer and poor outcomes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Erectile dysfunction (ED) affects millions globally, characterized by the inability to achieve or maintain an erection. This review covers current ED treatments and discusses emerging strategies for improved erectile function.

Area of Science:

  • Urology
  • Andrology
  • Sexual Medicine

Background:

  • Erectile dysfunction (ED) is a prevalent male health issue impacting approximately 150 million men worldwide.
  • It is defined as the persistent inability to achieve and maintain a penile erection sufficient for satisfactory sexual intercourse.

Purpose of the Study:

  • To review the physiological mechanisms underlying penile erection.
  • To provide an overview of currently available oral pharmacotherapies for ED management.
  • To discuss novel and emerging therapeutic strategies aimed at enhancing erectile function.

Main Methods:

  • Literature review of physiological processes of penile erection.
  • Compilation and summary of established oral medications for ED.
  • Exploration of innovative treatment modalities and future therapeutic directions.

Related Experiment Videos

Main Results:

  • A wide array of ED management options exist, including oral agents (PDE5 inhibitors), intracavernosal injections, transurethral therapies, vacuum devices, surgery, and prostheses.
  • Oral phosphodiesterase type 5 (PDE5) inhibitors are a primary treatment modality.
  • The review synthesizes current knowledge and highlights areas for future research and development in ED treatment.

Conclusions:

  • Effective management of erectile dysfunction involves a comprehensive understanding of its physiology and available treatments.
  • Current therapeutic options offer significant benefits, but ongoing research is crucial for developing more advanced and personalized ED solutions.
  • Novel strategies hold promise for further improving outcomes and addressing unmet needs in the treatment of erectile dysfunction.